Drugs Information Online
Drugs and diseases reference index

Drugs and diseases reference index
Search
EN

Drugs A-Z List

Diseases & Conditions A-Z List

Herbs & Supplements

Medical Dictionary

Full Article

Popular Drugs

Popular Diseases & Conditions

Drugs reference index «Eculizumab»

Eculizumab


Eculizumab

Pronunciation: (E-kue-LIZ-oo-mab)Class: Monoclonal antibody

Trade Names:Soliris- Solution for injection; preservative-free 300 mg (10 mg/mL)

Pharmacology

Inhibits terminal complement-mediated intravascular hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Pharmacokinetics

Absorption

C max and C min by wk 26 are 194 and 97 mcg/mL, respectively.

Distribution

Vd is 7.7 L.

Elimination

The t ½ is 272 h.

Indications and Usage

Treatment of PNH to reduce hemolysis.

Contraindications

Unresolved Neisseria meningitidis infection; current vaccination against N. meningitidis .

Dosage and Administration

Adults

IV Administer a meningococcal vaccine at least 2 wk prior to starting eculizumab therapy and revaccinate according to current medical guidelines. Infuse eculizumab 600 mg every 7 days for the first 4 wk, then 900 mg 7 days later for the fifth dose, then 900 mg every 14 days thereafter.

General Advice

  • Administer by IV infusion over 35 min via gravity feed, syringe-type pump, or infusion pump.
  • Dilute to a final administration concentration of 5 mg/mL by adding the appropriate amount of sodium chloride 0.9% or 0.45%, dextrose 5% in water, or Ringer's injection.
  • Ensure thorough mixing by gently inverting the infusion bag.
  • Prior to administration, allow admixture to adjust to room temperature. Do not microwave or use heat source other than ambient air temperature.
  • Prior to administration, visually inspect product for particulate matter and discoloration.

Storage/Stability

Store in original container, under refrigeration between 36° and 46°F, until time of use. Protect from light. Do not freeze or shake. Admixed solution is stable for 2 h at 36° to 46°F and at room temperature.

Drug Interactions

None known.

Laboratory Test Interactions

None well documented.

Adverse Reactions

CNS

Headache (44%); fatigue (12%).

EENT

Nasopharyngitis (23%).

GI

Nausea (16%); constipation (7%).

Musculoskeletal

Back pain (19%); myalgia (7%).

Respiratory

Cough (12%); respiratory tract infection, sinusitis (7%).

Miscellaneous

Herpes simplex infections, pain in extremities (7%); flu-like illness (5%); pyrexia, viral infection (2%).

Precautions

Warnings

Eculizumab increases the risk of meningococcal infections. Vaccinate patients according to current medical guidelines at least 2 wk prior to administering the first dose of eculizumab. Monitor patients for early signs of meningococcal infections and evaluate immediately if infection is suspected; treat with antibiotics if necessary.

Monitor

Monitor for serious hemolysis and other reactions for at least 8 wk after discontinuing treatment.

Pregnancy

Category C .

Lactation

Undetermined.

Children

Safety and efficacy not established.

Infection

Risk of infection, especially with encapsulated bacteria, is increased. Use with caution in patients with systemic infection.

Infusion reactions

As with any protein product, anaphylaxis or other hypersensitivity reactions may occur. Interrupt treatment and administer medical therapy if a severe infusion reaction occurs.

Overdosage

Symptoms

No cases reported.

Patient Information

  • Advise patient to read the Medication Guide before using product for the first time and with each refill.
  • Inform patient of the need to receive meningococcal vaccination at least 2 wk prior to starting therapy.
  • Educate patients about signs and symptoms of meningococcal infection and advise them to seek immediate medical attention if they experience the following: confusion, fever and rash, fever of 103°F or higher, moderate to severe headache and fever, moderate to severe headache with nausea or vomiting, moderate to severe headache with stiff neck or stiff back, severe muscle aches with flu-like symptoms, and eyes sensitive to light.
  • Instruct patient to carry the provided patient safety card at all times.
  • Inform patients of the risk of serious hemolysis when treatment is discontinued and that they need to be monitored for at least 8 wk after completion of treatment.

Copyright © 2009 Wolters Kluwer Health.

  • Eculizumab MedFacts Consumer Leaflet (Wolters Kluwer)
  • eculizumab Intravenous Advanced Consumer (Micromedex) - Includes Dosage Information
  • Soliris Consumer Overview

See Also...

Comment «Eculizumab»